The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity

Last updated: December 4, 2007
Sponsor: Affective Neuroscience Laboratory
Overall Status: Completed

Phase

1

Condition

Affective Disorders

Depression

Mood Disorders

Treatment

N/A

Clinical Study ID

NCT00205946
2004-P-002234-1
2004-P002234-1
  • Ages 18-64
  • All Genders

Study Summary

The purpose of the study is to evaluate the effects of a single-dose of Wellbutrin XL (bupropion hydrochloride) on reward processing.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Absence of medical, neurological, and psychiatric illness (including alcohol andsubstance abuse)

  • Non-Smoker

  • Right-handed (Chapman and Chapman 1987)

  • Ability to provide informed consent

Exclusion

Exclusion Criteria:

  • Predisposition to seizure (e.g. family history of a seizure disorder, history of headtrauma) or current use of medications that lower the seizure threshold

  • History or current diagnosis of anorexia or bulimia

  • Alcohol or substance abuse within the past year

  • Current usage of Wellbutrin or Zyban or other drugs that contain bupropion

  • Recent discontinuation of alcohol or sedatives (including benzodiazepines)

  • Use of (in the last 2 weeks) medications that may have antidepressant properties (ex.some herbal supplements)

  • Known allergies to bupropion

  • Currently lactating, pregnant or believe you are likely to be pregnant (enrolledsubjects who are not using reliable contraception and have engaged in sexualintercourse since their last menstrual period will be given a self-administeredpregnancy test.)

  • Left-handed/ambidextrous

  • Evidence of neurological illness

  • Serious suicide or homicide risk Concomitant medications other than those listed in the exclusion criteria will beconsidered on an individual basis. Oral contraceptives will be allowed.

Study Design

Total Participants: 32
Study Start date:
April 01, 2005
Estimated Completion Date:
July 31, 2007

Study Description

A cardinal feature of Major Depressive Disorder is anhedonia, which is a lack of pleasure in normally enjoyable activities. In order to understand reward processing in depressed individuals it is also necessary to study reward processing in people who are not depressed. Bupropion, the active drug in the anti-depressant Wellbutrin XL, has been shown to increase brain reward functioning in animals. The goal of the present study is to investigate the effects of Wellbutrin XL administered to psychiatrically healthy individuals as they perform a computer task known to assess reward processing.

Connect with a study center

  • The Depression Clinical and Research Program, Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • Affective Neuroscience Laboratory, Department of Psychology, Harvard University

    Cambridge, Massachusetts 02138
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.